137 related articles for article (PubMed ID: 15379950)
21. [Fulminant liver failure with a fatal outcome due to flutamide].
Fernández Peña CM; Morano Amado LE; Montes Santiago J; Fachal C
Med Clin (Barc); 1997 Feb; 108(6):237-8. PubMed ID: 9102495
[No Abstract] [Full Text] [Related]
22. Photosensitive drug eruption induced by flutamide.
Yokote R; Tokura Y; Igarashi N; Ishikawa O; Miyachi Y
Eur J Dermatol; 1998 Sep; 8(6):427-9. PubMed ID: 9729061
[TBL] [Abstract][Full Text] [Related]
23. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
24. Flutamide-induced photosensitivity: is it a forme fruste of lupus?
Kaur C; Thami GP
Br J Dermatol; 2003 Mar; 148(3):603-4. PubMed ID: 12653768
[No Abstract] [Full Text] [Related]
25. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
26. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
27. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Lloyd A; Penson D; Dewilde S; Kleinman L
Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
[TBL] [Abstract][Full Text] [Related]
28. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial.
Zalcberg JR; Raghaven D; Marshall V; Thompson PJ
Br J Urol; 1996 Jun; 77(6):865-9. PubMed ID: 8705223
[TBL] [Abstract][Full Text] [Related]
29. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
30. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
[TBL] [Abstract][Full Text] [Related]
31. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE
Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685
[TBL] [Abstract][Full Text] [Related]
32. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis.
Cicognani C; Malavolti M; Morselli-Labate AM; Sama C; Barbara L
Dig Dis Sci; 1996 Nov; 41(11):2219-21. PubMed ID: 8943975
[TBL] [Abstract][Full Text] [Related]
33. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
[TBL] [Abstract][Full Text] [Related]
35. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
36. [Fulminant hepatitis associated with treatment with flutamide].
García-Gascó P; Morata Aldea C; Segura Huertas A; Aparicio Urtasun J
Med Clin (Barc); 1997 Dec; 109(20):820. PubMed ID: 9493166
[No Abstract] [Full Text] [Related]
37. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer.
Wirth MP; Weissbach L; Marx FJ; Heckl W; Jellinghaus W; Riedmiller H; Noack B; Hinke A; Froehner M
Eur Urol; 2004 Mar; 45(3):267-70; discussion 270. PubMed ID: 15036669
[TBL] [Abstract][Full Text] [Related]
38. Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Whelan P
Eur Urol; 2008 Oct; 54(4):823-4. PubMed ID: 18243509
[No Abstract] [Full Text] [Related]
39. Prostate cancer with multiple lung metastases in a hemodialysis patient.
Hayakawa K; Matsumoto M; Aoyagi T; Miyaji K; Hata M
Int J Urol; 2000 Dec; 7(12):464-6. PubMed ID: 11168686
[TBL] [Abstract][Full Text] [Related]
40. Response of bidimensionally measurable metastases to flutamide withdrawal in a patient with advanced prostate cancer.
Warren GP; Roth BJ
Indiana Med; 1996; 89(3):274-7. PubMed ID: 8675981
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
